Agteria Biotech

The company's core product is a patent-pending molecule, AB-01, which functions as an enzyme-blocking agent when added to cattle feed. This molecule, a stable powder, is designed to be easily integrated into various feeding systems, including being premixed into minerals for feedlot animals or formulated for precise dosing for grazing cattle. In-vivo trials have shown the additive can cut enteric methane emissions by up to 70% without adverse effects on the animals. Agteria Biotech states its solution is designed to be scalable and affordable, offering a high methane reduction per euro spent.

Agteria Biotech's business model involves selling its molecule to mineral and animal feed companies. These companies can then incorporate it into their products for the beef and dairy industries, which are facing pressure to reduce their substantial greenhouse gas footprints. The firm has attracted interest and secured Letters of Intent from major European players in these sectors. To fund its path to commercialization, Agteria Biotech has raised significant capital. After an initial accelerator round in late 2023, it secured €1.4 million in a pre-seed round in March 2024, followed by a €6 million seed round in February 2025. The funding is being used to advance the product through regulatory approval by conducting safety studies for animals, consumers, and the environment, with a goal of beginning commercial sales by 2026.